Avantax Planning Partners’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Avantax Planning Partners’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-74	Closed	–	–	1482
2018 Q3	$0	Buy	+74	New	+$17	﹤0.01%	1480
2018 Q2	–	Sell	-74	Closed	–	–	1889
2018 Q1	$0	Buy	+74	New	+$20	﹤0.01%	1911

Other funds holding IMUC

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Avantax Planning Partners's IMUC Position: Q4 2018 in Review

Avantax Planning Partners sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 74 shares.

Avantax Planning Partners first reported a position in IMUC in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2018. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

Avantax Planning Partners reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
Avantax Planning Partners sold 74 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018.
Avantax Planning Partners first reported a position in ImmunoCellular Therapeutics, Ltd. in Q1 2018 and held it in 2 quarters.
Avantax Planning Partners's ImmunoCellular Therapeutics, Ltd. position peaked at $0 in Q3 2018.
3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.